Cowen Downgrades Accretive Health (ACHI) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Accretive Health (ACHI) PT Cut to $2.70 at Piper Jaffray as Ascension Walks
July 17, 2015 7:07 AM EDTPiper Jaffray analyst Sean Wieland reiterated an Underweight rating and lowered his price target on Accretive Health (OTC: ACHI) to $2.70 (from $7.00) following an ultimatum from Ascension.
Wieland commented, "Ascension offered ACHI a choice: Be taken private at fifty cents on the dollar ($2.70/sh)... More
